COIOSDeep risk insights through multi-disciplinary research across the globe
a large building with a bridge going across it
Item new Peer-reviewed Added

Transvalvular pump in infarct-related cardiogenic shock costs €36,083 per QALY in Germany

A lifetime model puts a microaxial flow pump in infarct-related cardiogenic shock at €36,083 per QALY for German statutory insurers.

This study modelled the cost-effectiveness of a transvalvular microaxial flow pump in infarct-related cardiogenic shock, for German statutory insurers. A cohort state-transition model used trial outcomes for 180 days, then chronic states with or without heart failure. The pump gave 1.06 extra QALYs at €38,121 more, or €36,083 per QALY, discounted at 3%. At an illustrative threshold of €50,000 per QALY, the probability of cost-effectiveness was 86%. Bleeding (21.8% vs 11.9%) and limb ischaemia (5.6% vs 1.1%) were more frequent with the pump. Acute payments were assumed equal between arms, and net monetary benefit remained positive below an acute payment difference of €14,703.

Why it is interesting: The pump lowered 180-day mortality but raised bleeding and limb ischaemia, and the model weighs both. The result depends on acute hospital payments not yet measured by arm.

Source
Expert Review of Pharmacoeconomics & Outcomes Research, 18 November 2026
DOI
10.1080/14737167.2026.2767331
Type
Peer-reviewed article
Design
Cohort state-transition cost-utility model, German statutory health insurance perspective, lifetime horizon with 180-day acute phase from trial outcomes (NCT01633502), 2023 euros, 3% discounting, probabilistic and threshold sensitivity analysis
Verdict
New finding
Driver
Value in health
Driver
Heart and stroke

Other drivers in Data, models and systems